Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients

Amyotrophic Lateral Sclerosis

Volumn 13, Issue 3, 2012, Pages 265-269

  Ramos, Eliana Marisa ^a,b   Keagle, Pamela ^c   Gillis, Tammy ^a   Lowe, Patrick ^c   Mysore, Jayalakshmi S ^a   Leclerc, Ashley Lyn ^c   Ratti, Antonia ^d   Ticozzi, Nicola ^d   Gellera, Cinzia ^e   Gusella, James F ^a   Silani, Vincenzo ^d   Alonso, Isabel ^b   Brown, Robert H ^c   Macdonald, Marcy E ^a   Landers, John E ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Huntington's disease; Neurodegenerative disease; Polyglutamine expansion; Trinucleotide repeat

Indexed keywords

GENOMIC DNA; HUNTINGTIN;

ADULT; AGED; ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CAG REPEAT; CHROMOSOME; CHROMOSOME NUMBER; COHORT ANALYSIS; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NERVE CELL DEGENERATION; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84860387378     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2011.653573     Document Type: Article

References (30)

1. The Huntington s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington s disease chromosomes. Cell. 1993;72:971-83.
2. Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington s disease with 29 trinucleotide repeats. Mov Disord. 2007;22:127-30. (Pubitemid 46382686)
3. Eisen A, Mezei MM, Stewart HG, Fabros M, Gibson G, Andersen PM. SOD1 gene mutations in ALS patients from British Columbia, Canada: Clinical features, neurophysiology and ethical issues in management. Amyotroph Lateral Scler. 2008;9:108-19. (Pubitemid 351584037)
4. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C , et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572-4. (Pubitemid 351601218)
5. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668-72. (Pubitemid 351432505)
6. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205-8.
7. Vance C, Rogelj B, Hortobagyi T, de Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208-11.
8. Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem. 2010;285:26304-14.
9. Doi H, Koyano S, Suzuki Y, Nukina N, Kuroiwa Y. The RNA-binding protein FUS/TLS is a common aggregateinteracting protein in polyglutamine diseases. Neurosci Res. 2010;66:131-3.
10. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington s disease. J Neuropathol Exp Neurol. 2008;67:1159-65.
11. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223-6.
12. del Bo R, Tiloca C, Pensato V, Corrado L, Ratti A, Ticozzi N, et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:1239-43.
13. Hortobagyi T, Troakes C, Nishimura AL, Vance C, van Swieten JC, Seelaar H, et al. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol. 2011;121:519-27.
14. del Toro D, Alberch J, Lazaro-Dieguez F, Martin-Ibanez R, Xifro X, Egea G, et al. Mutant huntingtin impairs post-Golgi traffi cking to lysosomes by delocalizing optineurin/Rab8 complex from the Golgi apparatus. Mol Biol Cell. 2009;20:1478-92.
15. Dejesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC Hexanucleotide Repeat in Non-coding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245-56.
16. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257-68.
17. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069-75.
18. Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011;20: 1697-700.
19. van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, Thijs V, et al. Expanded ATXN2 CAG repeat size in ALS identifi es genetic overlap between ALS and SCA2. Neurology. 2011;76:2066-72.
20. Perlis RH, Smoller JW, Mysore J, Sun M, Gillis T, Purcell S, et al. Prevalence of incompletely penetrant Huntington s disease alleles among individuals with major depressive disorder. Am J Psychiatry. 2010;167:574-9.
21. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington s disease chromosomes. Mol Cell Probes. 1993;7:235-9. (Pubitemid 23232244)
22. Andresen JM, Gayan J, Djousse L, Roberts S, Brocklebank D, Cherny SS, et al. The relationship between CAG repeat length and age of onset differs for Huntington s disease patients with juvenile onset or adult onset. Ann Hum Genet. 2007;71:295-301. (Pubitemid 46585671)
23. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319: 916-9. (Pubitemid 351263754)
24. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311:1471-4. (Pubitemid 43376703)
25. Rubio A, Steinberg K, Figlewicz DA, MacDonald ME, Greenamyre T, Hamill R, et al. Coexistence of Huntington s disease and familial amyotrophic lateral sclerosis: Case presentation. Acta Neuropathol. 1996;92:421-7. (Pubitemid 26317111)
26. Sadeghian H, O Suilleabhain PE, Battiste J, Elliott JL, Trivedi JR. Huntington chorea presenting with motor neuron disease. Arch Neurol. 2011;68:650-2.
27. Gamez J, Corbera-Bellalta M, Mila M, Lopez-Lisbona R, Boluda S, Ferrer I. Chorea-ballism associated with familial amyotrophic lateral sclerosis: A clinical, genetic, and neuropathological study. Mov Disord. 2008;23:434-8.
28. Pradat PF, Salachas F, Lacomblez L, Patte N, Leforestier N, Gaura V, et al. Association of chorea and motor neuron disease. Mov Disord. 2002;17:419-20. (Pubitemid 36054152)
29. Lee T, Li YR, Chesi A, Hart MP, Ramos D, Jethava N, et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology. 2011;76: 2062-5.
30. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, de Jesus-Hernandez M, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011;20:3207-12.